# Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

> **NCT04186403** · PHASE2,PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 201 (actual)

## Conditions studied

- Borderline Personality Disorder

## Interventions

- **DRUG:** Brexpiprazole

## Key facts

- **NCT ID:** NCT04186403
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-13
- **Primary completion:** 2021-09-22
- **Final completion:** 2021-09-22
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04186403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04186403, "Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04186403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*